Force Majeure: Therapeutic measures in response to restricted supply of imiglucerase (Cerezyme) for patients with Gaucher disease

Blood Cells, Molecules, and Diseases

Volumn 44, Issue 1, 2010, Pages 41-47

  Hollak, Carla E M ^a   vom Dahl, Stephan ^b   Aerts, Johannes M F G ^a   Belmatoug, Nadia ^c   Bembi, Bruno ^d   Cohen, Yossi ^e   Collin Histed, Tanya ^e   Deegan, Patrick ^f   van Dussen, Laura ^a   Giraldo, Pilar ^g   Mengel, Eugen ^h   Michelakakis, Helen ⁱ   Manuel, Jeremy ^e   Hrebicek, Martin ^j   Parini, Rosella ^k   Reinke, Jörg ^h   di Rocco, Maja ^m   Pocovi, Miguel ^l   Sa Miranda, Maria Clara ⁿ   Tylki Szymanska, Anna ^o   Zimran, Ari ^p   Cox, Timothy M ^f   more..

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b St Franziskus Hospital Koln   (Germany)

^c BEAUJON HOSPITAL   (France)

^d Ospedale Universitario   (Italy)

^e EGA   (United Kingdom)

^f UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^g HOSPITAL UNIVERSITARIO MIGUEL SERVET   (Spain)

^h UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

ⁱ Institute of Child Health   (Greece)

^j Charles University in Prague and General University Hospital in Prague   (Czech Republic)

^k SAN GERARDO HOSPITAL   (Italy)

^l UNIVERSITY OF ZARAGOZA   (Spain)

^m G GASLINI INSTITUTE   (Italy)

ⁿ UNIVERSITY OF PORTO   (Portugal)

^o CHILDREN'S MEMORIAL HEALTH INSTITUTE   (Poland)

^p SHAARE ZEDEK MEDICAL CENTER   (Israel)

more..

Author keywords

Cerezyme; Europe; Gaucher disease; Imiglucerase; Vesivirus

Indexed keywords

CERAMIDE GLUCOSYLTRANSFERASE INHIBITOR; GENZ 112638; IDURONATE 2 SULFATASE; IMIGLUCERASE; MIGLUSTAT; TALIGLUCERASE; UNCLASSIFIED DRUG; VELAGLUCERASE; VELAGLUCERASE ALFA;

ARTICLE; BLOOD CELL COUNT; CLINICAL TRIAL; DRUG APPROVAL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MANUFACTURE; DRUG MARKETING; GAUCHER DISEASE; HEALTH CARE ACCESS; HEALTH CARE DISTRIBUTION; HEALTH CARE POLICY; HIGH RISK POPULATION; HUMAN; HUNTER SYNDROME; LONG TERM CARE; LOW DRUG DOSE; PATIENT MONITORING; PRACTICE GUIDELINE; PRIORITY JOURNAL; RESOURCE ALLOCATION; TREATMENT PLANNING; VIRAL CONTAMINATION;

1-DEOXYNOJIRIMYCIN; AFRICA, NORTHERN; COMPASSIONATE USE TRIALS; DRUG CONTAMINATION; DRUGS, INVESTIGATIONAL; ENZYME INHIBITORS; ENZYME REPLACEMENT THERAPY; EQUIPMENT CONTAMINATION; EUROPE; GAUCHER DISEASE; GLUCOSYLCERAMIDASE; GUIDELINES AS TOPIC; HEALTH CARE RATIONING; HEALTH PRIORITIES; HUMANS; INTERNATIONAL COOPERATION; MIDDLE EAST; RECOMBINANT PROTEINS; VESIVIRUS;

VESIVIRUS;

EID: 73049102077     PISSN: 10799796     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcmd.2009.09.006     Document Type: Article

References (23)

1. Brady R.O., Kanfer J.N., and Shapiro D. Metabolism of glucocerebrosides, II: evidence of an enzymatic deficiency in Gaucher's disease. Biochem. Biophys. Res. Commun. 18 (1965) 221-225
2. Patrick A.D. Short communications: a deficiency of glucocerebrosidase in Gaucher's disease. Biochem. J. (1955) 97
3. Sidransky E. Gaucher disease: complexity in a "simple" disorder. Mol. Genet. Metab. 83 (2004) 6-15
4. Cox T.M., and Schofield J.P. Gaucher's disease: clinical features and natural history. Baillieres Clin. Haematol. 10 (1997) 657-689
5. Beutler E., and Grabowski G.A. Gaucher disease. In: Scriver C.R., Beaudet A.L., Sly W.S., and Valle D. (Eds). The Metabolic and Molecular Bases of Inherited Disease (2001), McGraw-Hill, New York 3636
6. Barton N.W., Brady R.O., Dambrosia J.M., Di Bisceglie A.M., et al. Replacement therapy for inherited enzyme deficiency - macrophage-targeted glucocerebrosidase for Gaucher's disease. N. Engl. J. Med. 324 (1991) 1464-1470
7. Grabowski G.A., Barton N.W., Pastores G., Dambrosia J.M., et al. Enzyme therapy in type 1 Gaucher disease: comparative efficacy of mannose-terminated glucocerebrosidase from natural and recombinant sources. Ann. Intern. Med. 122 (1995) 33-39
8. Zimran A., Elstein D., Levy-Lahad E., Zevin S., et al. Replacement therapy with imiglucerase for type 1 Gaucher's disease. Lancet 345 8963 (1995) 1479-1480
9. Zimran A., Loveday K., Fratazzi C., and Elstein D. A pharmacokinetic analysis of a novel enzyme replacement therapy with gene-activated(R) human glucocerebrosidase (GA-GCB) in patients with type 1 Gaucher disease. Blood Cells Mol. Dis. 39 1 (2007) 115-118
10. Aviezer D., Brill-Almon E., Shaaltiel Y., Hashmueli S., et al. A plant-derived recombinant human glucocerebrosidase enzyme - a preclinical and phase I investigation. PLoS ONE 4 3 (2009) e4792
11. Cox T.M., Aerts J.M., Andria G., Beck M., et al. The role of the iminosugar N-butyldeoxynojirimycin (miglustat) in the management of type I (non-neuronopathic) Gaucher disease: a position statement. J. Inherit. Metab. Dis. 26 (2003) 513-526
12. European Medicines Agency (EMEA). PRESS RELEASE. Supply shortages of Cerezyme and Fabrazyme - priority access for patients most in need of treatment recommended. 25-6-2009.
13. Elstein D., Abrahamov A., Hadas-Halpern I., and Zimran A. Withdrawal of enzyme replacement therapy in Gaucher's disease. Br. J. Haematol. 110 (2000) 488-492
14. vom Dahl S., Poll L.W., and Haussinger D. Clinical monitoring after cessation of enzyme replacement therapy in M. Gaucher. Br. J. Haematol. 113 (2001) 1084-1087
15. Schwartz I.V., Karam S., Ashton-Prolla P., Michelin K., et al. Effects of imilglucerase withdrawal on an adult with Gaucher disease. Br. J. Haematol. 113 (2001) 1089
16. Grinzaid K.A., Geller E., Hanna S.L., and Elsas L.J. Cessation of enzyme replacement therapy in Gaucher disease. Genet. Med. 4 (2002) 427-433
17. Toth J., Erdos M., and Marodi L. Rebound hepatosplenomegaly in type 1 Gaucher disease. Eur. J. Haematol. 70 (2003) 125-128
18. Drelichman G., Ponce E., Basack N., et al. Clinical consequences of interrupting enzyme replacement therapy in children with type 1 Gaucher disease. J. Pediatr. 151 (2007) 197-201
19. U.S. Cerezyme Stakeholders Working Group. Revised Guidance to the U.S. Gaucher Community: Management of Cerezyme® (imiglucerase for injection) Supply. 10-8-2009.
20. European Medicines Agency (EMEA). Questions and answers on the shortages of Cerezyme and Fabrazyme. 14-8-2009.
21. Hollak C.E.M., Aerts J.M., Goudsmit R., Phoa S.S., et al. Individualised low-dose alglucerase therapy for type 1 Gaucher's disease. Lancet 345 (1995) 1474-1478
22. Giraldo P., Alfonso P., Atutxa K., Fernández-Galán M.A., et al. Real-world clinical experience with long-term miglustat maintenance therapy in type 1 Gaucher disease: the ZAGAL project. Haematologica (2009) (Jul 16 Electronic publication ahead of print).
23. Pastores G.M., Elstein D., Hrebícek M., and Zimran A. Effect of miglustat on bone disease in adults with type 1 Gaucher disease: a pooled analysis of three multinational, open-label studies. Clin. Ther. 29 (2007) 1645-1654